Main Sequence Ventures

The partnership committee including Mike Zimmerman, Martin Duursma, and Gabrielle Munzer makes investment decisions, with final sign-off distributed across the GP team rather than concentrated in a single CIO. The firm also relies on a network of CSIRO scientists who provide pre-diligence technical assessments that influence whether a deal reaches the full partnership review stage.

The firm's structural advantage is its embedded relationship with CSIRO, which gives it early visibility into publicly funded deep-tech research across Australia. Scientists and postdoctoral teams working inside CSIRO's labs often approach the firm before incorporating a separate legal entity, creating a sourcing pipeline that is difficult for external VCs to replicate. The firm also runs a creator-community program that introduces university spinout founders to its thematic objectives.

It operates purely as a venture-capital firm. Despite the CSIRO anchor, Main Sequence is a fund manager with a diversified institutional LP base that includes Australian superannuation funds such as Hostplus and international sovereign allocators such as Temasek. It is not a captive corporate-venture arm and faces the same return expectations as any independent GP.

The firm covers pre-seed through Series B, with initial checks that scale from AUD 250,000 for pre-company formation science projects up to AUD 15 million for expansion rounds. It reserves material follow-on capital to support portfolio companies into international Series C rounds, often syndicating with US and European deep-tech funds at that stage.

The firm avoids SaaS businesses without a defensible scientific moat and has publicly stated it does not invest in enterprise-software companies that lack a hardware, biological, or physical-chemistry component (per AFR, 2021). Consumer-internet and fintech-lending models also fall outside its three named thematic streams.

Main Sequence was launched in 2017 with CSIRO as its founding limited partner and retains a first-look agreement on research emanating from CSIRO's labs. CSIRO does not control the investment committee, but its scientists participate in technical due-diligence reviews, and the firm's Canberra office is co-located with CSIRO's major research facilities. The relationship functions as a sourcing mechanism, not a captive funding mandate.

Main Sequence deploys capital exclusively through direct equity investments into operating companies. It is not a fund-of-funds and does not allocate to external managers. On occasion, the firm structures co-investment alongside its own primary commitment, particularly when a syndicate requires a follow-on vehicle architecture, but it has never acted as a passive LP in another venture firm.